Definitions of the levels of the recommendations (A, B, C, U) and classification of the evidence (Class I through Class IV) are provided at the end of the "Major Recommendations" field.
Upper Extremity Spasticity and Lower Extremity Spasticity in Adults
Conclusions
Botulinum neurotoxin (BoNT) is established as effective in the treatment of adult spasticity in the upper and lower limb in reducing muscle tone and improving passive function (14 Class I studies). While relatively few studies examined active function, recent data suggest that BoNT is probably effective in improving active function (one Class I study). There are inadequate data to determine if electrical stimulation or electromyography (EMG) techniques for optimal muscle localization improves outcome.
Recommendations
- BoNT should be offered as a treatment option to reduce muscle tone and improve passive function in adults with spasticity (Level A), and should be considered to improve active function (Level B).
- There is insufficient evidence to recommend an optimum technique for muscle localization at the time of injection (Level U).
Spasticity Due to Cerebral Palsy in Children
Conclusions
BoNT injection of the gastrocnemius-soleus muscles is established as effective in the treatment of spastic equinus in patients with cerebral palsy (CP) (four Class I studies). There is insufficient evidence to support or refute the benefit of additional casting to BoNT injection of the gastrocnemius-soleus muscles (inconsistent Class II and III studies) and the injection of BoNT into the hamstrings (only Class IV studies). In patients with adductor spasticity, BoNT injection is probably effective in improving adductor spasticity and range of motion (one Class I study), as well as postoperative pain in children undergoing adductor muscle lengthening surgery (one Class I study). In patients with upper extremity symptoms, BoNT injection is probably effective in improving spasticity and range of motion (two Class II studies and one Class III study).
Recommendations
- BoNT injection of the calf muscles should be offered as a treatment option for equinus varus deformity in children with cerebral palsy (Level A).
- BoNT injection should be considered as a treatment option for treatment of adductor spasticity and for pain control in children undergoing adductor-lengthening surgery (Level B).
- BoNT injection should be considered as a treatment option in children with upper extremity spasticity (Level B).
Definitions:
Classification of Recommendations
Level A = Established as effective, ineffective, or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies*)
Level B = Probably effective, ineffective, or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)
Level C = Possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)
Level U = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven. (Studies not meeting criteria for Class I–III.)
*In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome >5 and the lower limit of the confidence interval is >2).
Classification of Evidence for Therapeutic Intervention
Class I: Randomized, controlled clinical trial with masked or objective outcome assessment in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences. The following are required: a) concealed allocation, b) primary outcome(s) clearly defined, c) exclusion/inclusion criteria clearly defined, and d) adequate accounting for drop-outs (with at least 80% of enrolled subjects completing the study) and cross-overs with numbers sufficiently low to have minimal potential for bias.
Class II: Prospective matched group cohort study in a representative population with masked outcome assessment that meets b-d above OR a randomized controlled trial in a representative population that lacks one criteria a-d.
Class III: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.*
Class IV: Studies not meeting Class I, II, or III criteria, including consensus, expert opinion, or a case report.
* Objective outcome measurement: An outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).